MedPath

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Phase 2
Active, not recruiting
Conditions
Non-small Cell Lung Cancer
Metastatic Non-small Cell Lung Cancer
Interventions
Registration Number
NCT05635708
Lead Sponsor
BeiGene
Brief Summary

The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy. This study is structured as a master protocol with separate sub- studies. Sub-study 1 includes participants with non-small cell lung cancer (NSCLC) with high programmed cell death protein ligand-1 (PD-L1) expression (≥ 50%), and Sub-study 2 includes participants with NSCLC with low or negative (PD-L1) expression (\< 50%).

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
400
Inclusion Criteria
  1. Histologically or cytologically confirmed non-small cell lung cancer (NSCLC), including nonsquamous or squamous subtypes, that is either locally advanced or recurrent and not eligible for curative surgery and/or definitive chemoradiotherapy, or metastatic NSCLC.
  2. No prior systemic therapy administered as the primary treatment for metastatic NSCLC. Prior adjuvant or neoadjuvant chemotherapy, definitive chemoradiation, or adjuvant radiotherapy for locally advanced disease is permitted, provided the last dose of chemotherapy and/or radiotherapy occurred at least 6 months prior to randomization/enrollment.
  3. Tumor programmed death-ligand 1 (PD-L1) expression must be evaluable, as determined by a local or central laboratory using archival tumor tissue or a fresh biopsy. Participants with unknown PD-L1 expression are not eligible.
  4. At least one measurable lesion, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
  5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

Key

Exclusion Criteria
  1. Diagnosis of mixed small cell lung cancer.

  2. Known genomic alterations for which effective targeted therapies are available according to local standard of care, including but not limited to:

    • Epidermal growth factor receptor (EGFR) mutations
    • Anaplastic lymphoma kinase (ALK) rearrangements
    • B-Raf proto-oncogene (BRAF) mutations
    • Rearranged during transfection (RET) fusions
    • c-ros oncogene 1 (ROS1) rearrangements
  3. Participants with nonsquamous NSCLC and unknown EGFR mutation status must undergo local testing. Those found to have EGFR-sensitizing mutations will be excluded.

  4. Prior treatment with immune-based therapies that target immune checkpoint pathways, including:

    • PD-1 (programmed cell death protein 1) inhibitors
    • PD-L1 (programmed death-ligand 1) inhibitors
    • PD-L2 (programmed death-ligand 2) inhibitors
    • TIGIT (T cell immunoreceptor with Ig and ITIM domains) inhibitors
    • LAG-3 (lymphocyte activation gene 3) inhibitors
  5. Participants previously treated with these agents in a neoadjuvant, adjuvant, or consolidation setting may be eligible if a treatment-free interval of at least 6 months has elapsed since the last dose and radiologic evidence of recurrence is present.

  6. Use of Chinese herbal medicines or Chinese patent medicines intended for cancer control within 14 days prior to randomization/enrollment.

  7. Presence of active leptomeningeal disease, untreated or uncontrolled brain metastases, or active autoimmune disease.

Note: Additional protocol-defined and sub-study-specific criteria may apply.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Sub-study 1: Arm 1ATislelizumabTislelizumab + BGB-A445
Sub-study 1: Arm 1ABGB-A445Tislelizumab + BGB-A445
Sub-study 1: Arm 2ATislelizumabTislelizumab + LBL-007
Sub-study 1: Arm 2ALBL-007Tislelizumab + LBL-007
Sub-study 1: Arm 3ATislelizumabTislelizumab + BGB-15025
Sub-study 1: Arm 3ABGB-15025Tislelizumab + BGB-15025
Sub-study 1: Reference Arm Tislelizumab aloneTislelizumabTislelizumab alone
Sub-study 2: Arm 1BTislelizumabTislelizumab + investigator's choice of histology-appropriate chemotherapy + BGB-A445
Sub-study 2: Arm 1BBGB-A445Tislelizumab + investigator's choice of histology-appropriate chemotherapy + BGB-A445
Sub-study 2: Arm 1BCarboplatinTislelizumab + investigator's choice of histology-appropriate chemotherapy + BGB-A445
Sub-study 2: Arm 1BCisplatinTislelizumab + investigator's choice of histology-appropriate chemotherapy + BGB-A445
Sub-study 2: Arm 1BpemetrexedTislelizumab + investigator's choice of histology-appropriate chemotherapy + BGB-A445
Sub-study 2: Arm 1BPaclitaxelTislelizumab + investigator's choice of histology-appropriate chemotherapy + BGB-A445
Sub-study 2: Arm 1BNab paclitaxelTislelizumab + investigator's choice of histology-appropriate chemotherapy + BGB-A445
Sub-study 2: Arm 2BTislelizumabTislelizumab + investigator's choice of histology-appropriate chemotherapy + LBL-007
Sub-study 2: Arm 2BLBL-007Tislelizumab + investigator's choice of histology-appropriate chemotherapy + LBL-007
Sub-study 2: Arm 2BCarboplatinTislelizumab + investigator's choice of histology-appropriate chemotherapy + LBL-007
Sub-study 2: Arm 2BCisplatinTislelizumab + investigator's choice of histology-appropriate chemotherapy + LBL-007
Sub-study 2: Arm 2BpemetrexedTislelizumab + investigator's choice of histology-appropriate chemotherapy + LBL-007
Sub-study 2: Arm 2BPaclitaxelTislelizumab + investigator's choice of histology-appropriate chemotherapy + LBL-007
Sub-study 2: Arm 2BNab paclitaxelTislelizumab + investigator's choice of histology-appropriate chemotherapy + LBL-007
Sub-study 2: Arm 3BTislelizumabTislelizumab + investigator's choice of histology-appropriate chemotherapy + BGB-15025
Sub-study 2: Arm 3BCarboplatinTislelizumab + investigator's choice of histology-appropriate chemotherapy + BGB-15025
Sub-study 2: Arm 3BCisplatinTislelizumab + investigator's choice of histology-appropriate chemotherapy + BGB-15025
Sub-study 2: Arm 3BpemetrexedTislelizumab + investigator's choice of histology-appropriate chemotherapy + BGB-15025
Sub-study 2: Arm 3BPaclitaxelTislelizumab + investigator's choice of histology-appropriate chemotherapy + BGB-15025
Sub-study 2: Arm 3BNab paclitaxelTislelizumab + investigator's choice of histology-appropriate chemotherapy + BGB-15025
Sub-study 2: Arm 3BBGB-15025Tislelizumab + investigator's choice of histology-appropriate chemotherapy + BGB-15025
Sub-study 2: Reference ArmTislelizumabTislelizumab + investigator's choice of histology-appropriate chemotherapy
Sub-study 2: Reference ArmCarboplatinTislelizumab + investigator's choice of histology-appropriate chemotherapy
Sub-study 2: Reference ArmCisplatinTislelizumab + investigator's choice of histology-appropriate chemotherapy
Sub-study 2: Reference ArmpemetrexedTislelizumab + investigator's choice of histology-appropriate chemotherapy
Sub-study 2: Reference ArmPaclitaxelTislelizumab + investigator's choice of histology-appropriate chemotherapy
Sub-study 2: Reference ArmNab paclitaxelTislelizumab + investigator's choice of histology-appropriate chemotherapy
Primary Outcome Measures
NameTimeMethod
Confirmed overall response rate (ORR)Up to 6 months

ORR is defined as the percentage of participants with partial or complete response, as assessed by the investigator using the Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1

Secondary Outcome Measures
NameTimeMethod
Progression-free survival (PFS)Up to 1 year

PFS is defined as the time from date of randomization, or the first dose for safety lead-in participants , until first documentation of progression or death, whichever comes first, as assessed by the investigator using RECIST v1.

Duration of Response (DOR)Up to 1 year

DOR is defined as the time from the first determination of a confirmed response per RECIST v1.1 until the first documentation of progression or death, whichever comes first as assessed by the investigator

Clinical Benefit Rate (CBR)Up to 6 months

CBR is defined as the percentage of participants with a best overall response of a complete response, partial response, or durable stable disease, as assessed by the investigator using RECIST v1.1

Disease Control Rate (DCR)Up to 6 months

DCR is defined as the percentage of participants with a best overall response of complete response, partial response, or stable disease, as assessed by the investigator using RECIST v1.1

Number of participants with adverse events (AEs)From the first dose of study drug(s) to 90 days after initiation of new anticancer therapy, death, withdrawal of consent, or loss to follow-up, whichever occurs first, up to approximately 2 years

Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including laboratory values, vital signs, physical examination findings, and electrocardiogram results.

Trial Locations

Locations (65)

Regina Elena, Istituto Nazionale Dei Tumori, Ifo, Irccs

🇮🇹

Roma, Italy

Centro Ricerche Cliniche Di Verona

🇮🇹

Verona, Italy

Tengku Ampuan Afzan Hospital

🇲🇾

Kuantan, Malaysia

St John of God Health Care

🇦🇺

Subiaco, Western Australia, Australia

Hospital de Amor Barretos

🇧🇷

Barretos, Brazil

Shanghai East Hospital Branch Hospital

🇨🇳

Shanghai, Shanghai, China

Hospital Do Cancer de Londrina

🇧🇷

Londrina, Brazil

Valkyrie Clinical Trials

🇺🇸

Los Angeles, California, United States

Hoag Memorial Presbyterian

🇺🇸

Newport Beach, California, United States

Massachusetts General Hospital

🇺🇸

Boston, Massachusetts, United States

Memorial Sloan Kettering Cancer Center Mskcc

🇺🇸

New York, New York, United States

Providence Portland Medical Center

🇺🇸

Portland, Oregon, United States

Oncology and Hematology Care Clinic Westside

🇺🇸

Portland, Oregon, United States

The University of Texas Md Anderson Cancer Center

🇺🇸

Houston, Texas, United States

Blacktown Cancer and Haematology Centre

🇦🇺

Blacktown, New South Wales, Australia

Chris Obrien Lifehouse

🇦🇺

Camperdown, New South Wales, Australia

Northern Beaches Hospital

🇦🇺

Frenchs Forest, New South Wales, Australia

Port Macquarie Base Hospital

🇦🇺

Port Macquarie, New South Wales, Australia

One Clinical Research

🇦🇺

Nedlands, Western Australia, Australia

Centro Gaucho Integrado de Oncologia Hospital Mae de Deus

🇧🇷

Porto Alegre, Brazil

Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto

🇧🇷

Sao Jose Do Rio Preto, Brazil

The Second Hospital of Anhui Medical University

🇨🇳

Hefei, Anhui, China

The Fifth Medical Center of Chinese Pla General Hospital

🇨🇳

Beijing, Beijing, China

Fujian Cancer Hospital

🇨🇳

Fuzhou, Fujian, China

Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira

🇧🇷

Sao Paulo, Brazil

Cross Cancer Institute

🇨🇦

Edmonton, Alberta, Canada

Affiliated Hospital of Hebei University

🇨🇳

Baoding, Hebei, China

Harbin Medical University Cancer Hospital

🇨🇳

Harbin, Heilongjiang, China

Henan Cancer Hospital

🇨🇳

Zhengzhou, Henan, China

Hubei Cancer Hospital

🇨🇳

Wuhan, Hubei, China

Nantong Tumor Hospital Branch North

🇨🇳

Nantong, Jiangsu, China

The First Affiliated Hospital of Soochow University

🇨🇳

Suzhou, Jiangsu, China

The First Affiliated Hospital of Nanchang University Branch Xianghu

🇨🇳

Nanchang, Jiangxi, China

Jining No Peoples Hospital East Branch

🇨🇳

Jining, Shandong, China

Linyi Peoples Hospital

🇨🇳

Linyi, Shandong, China

Affiliated Zhongshan Hospital of Fudan University

🇨🇳

Shanghai, Shanghai, China

Shanghai Pulmonary Hospital

🇨🇳

Shanghai, Shanghai, China

Shanxi Provincial Cancer Hospital

🇨🇳

Taiyuan, Shanxi, China

Tianjin Medical University Cancer Institute and Hospital

🇨🇳

Tianjin, Tianjin, China

Taizhou Hospital of Zhejiang

🇨🇳

Taizhou, Zhejiang, China

Institut Curie

🇫🇷

Paris, France

Chu Nantes Hopital Nord Laennec

🇫🇷

SaintHerblain, France

Arensia Exploratory Medicine Llc

🇬🇪

Tbilisi, Georgia

Chungbuk National University Hospital

🇰🇷

SeowonGu CheongjuSi, Chungcheongbukdo, Korea, Republic of

Seoul National University Bundang Hospital

🇰🇷

BundangGu SeongnamSi, Gyeonggi-do, Korea, Republic of

National Cancer Center (Korea)

🇰🇷

IlsandongGu GoyangSi, Gyeonggi-do, Korea, Republic of

The Catholic University of Korea, St Vincents Hospital

🇰🇷

PaldalGu SuwonSi, Gyeonggi-do, Korea, Republic of

Samsung Medical Center

🇰🇷

GangnamGu, Seoul Teugbyeolsi, Korea, Republic of

Severance Hospital Yonsei University Health System

🇰🇷

SeodaemunGu, Seoul Teugbyeolsi, Korea, Republic of

Asan Medical Center

🇰🇷

SongpaGu, Seoul Teugbyeolsi, Korea, Republic of

Pulau Pinang Hospital

🇲🇾

Georgetown, Malaysia

Sultan Ismail Hospital

🇲🇾

Johor Bahru, Malaysia

Sarawak General Hospital

🇲🇾

Kuching, Malaysia

Beacon Hospital

🇲🇾

Petaling Jaya, Malaysia

The Institute of Oncology, Arensia Exploratory Medicine

🇲🇩

Chisinau, Moldova, Republic of

Institute of Oncology Bucharest Prof Dr Alexandru Trestioreanu

🇷🇴

Bucureti, Romania

Arensia Research Clinic At the Oncology Institute Prof Dr Ion Chiricu

🇷🇴

ClujNapoca, Romania

National Cancer Centre Singapore

🇸🇬

Singapore, Singapore

Hospital Universitario Vall Dhebron

🇪🇸

Barcelona, Spain

Hospital Universitario de Octubre

🇪🇸

Madrid, Spain

Hospital Universitario Virgen Del Rocio

🇪🇸

Sevilla, Spain

Songklanagarind Hospital (Prince of Songkhla University)

🇹🇭

Hat Yai, Thailand

Srinagarind Hospital (Khon Kaen University)

🇹🇭

Muang, Thailand

Maharaj Nakorn Chiang Mai Hospital (Chiang Mai University)

🇹🇭

Muang, Thailand

Hrh Princess Maha Chakri Sirindhorn Medical Center (Srinakharinwirot University)

🇹🇭

Ongkharak, Thailand

© Copyright 2025. All Rights Reserved by MedPath